ClinicalTrials.gg
CompletedNCT03036150Dapa-CKDUpdated Jul 7, 2021Results posted

A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease

A Phase 3 interventional study of Dapagliflozin and Placebo in Chronic Kidney Disease, sponsored by AstraZeneca. Completed at 392 sites in 21 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2021-07-07.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
4,304
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 40 studies testing dapagliflozin in Renal Insufficiency, Chronic — 15 open to participants now, 21 under way, 7 of them phase 3. dapagliflozin · Renal Insufficiency, Chronic.

Enrollment
3rd of 40
4,304 · median 100
Started
2017
with 1 other
Phase 3
10 of 40
5 open now
Registered
2nd of 40
by date
Lead sponsor
9 of 40
AstraZeneca

Among the 40 studies testing dapagliflozin in Renal Insufficiency, Chronic, this one is the 3rd largest by enrollment, is one of 2 that started in 2017, is one of 10 in phase 3, and was the 2nd registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

15 of the 40 studies testing dapagliflozin in Renal Insufficiency, Chronic are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About dapagliflozin

dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 435 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 111 (26%) stop at 75 or younger; 45 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies testing dapagliflozin in Renal Insufficiency, Chronic, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effect of dapagliflozin on renal outcomes and cardiovascular mortality in patients with chronic kidney disease.

Read the detailed description

This is an international, multicentre, event-driven, randomized, double-blind, parallel group, placebo-controlled study, evaluating the effect of dapagliflozin versus placebo, given once daily in addition to standard of care, to prevent the progression of chronic kidney disease (CKD) or cardiovascular (CV)/renal death.

03

Conditions studied

  • Chronic Kidney Disease

Keywords

  • Chronic Kidney Disease (CKD)
  • Cardiovascular Events (CV)
  • Phase III outcome trial
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed prior to any study specific procedures
  • Female or male aged ≥18 years at the time of consent
  • ≥25 and ≤75 mL/min/1.73m2 (CKD-EPI Formula) at visit 1
  • Evidence of increased albuminuria 3 months or more before visit 1 and UACR ≥200 and ≤5000 mg/g at visit 1
  • Stable, and for the patient maximum tolerated labelled daily dose, treatment with ACE-I or ARB for at least 4 weeks before visit 1, if not medically ,

Exclusion criteria

Exclusion Criteria:

  • Autosomal dominant or autosomal recessive polycystic kidney disease, lupus nephritis or ANCA-associated vasculitis
  • Receiving cytotoxic therapy, therapy or other immunotherapy for primary or secondary renal disease within 6 months prior to enrolment
  • History of organ transplantation
  • Receiving therapy with an SGLT2 inhibitor within 8 weeks prior to enrolment or previous intolerance of an SGLT2 inhibitor
  • Type 1 diabetes mellitus
  • (NYHA) class IV Congestive Heart Failure at the time of enrolment
  • MI, unstable angina, stroke or within 12 weeks prior to enrolment
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
4,304 participants (actual)

Study arms

  • Experimental
    Dapagliflozin

    Patients will be randomized 1:1 to either dapagliflozin or placebo.

    Drug: Dapagliflozin

  • Placebo comparator
    Placebo

    Placebo matching dapagliflozin.

    Drug: Placebo

Interventions

  • 10 mg or 5 mg tablets given once daily, per oral use.

    Also known as: Forxiga TM, Farxiga TM

  • DrugPlacebo

    Placebo matching dapagliflozin 10 mg or 5 mg

06

What researchers measure

Primary outcomes

  1. Time to the First Occurrence of Any of the Components of the Composite: ≥50% Sustained Decline in eGFR or Reaching ESRD or CV Death or Renal Death.

    End Stage Renal Disease (ESRD) is defined as: * Sustained eGFR \<15 mL/min/1.73m2 or, * Chronic dialysis treatment or, * Receiving a renal transplant The proportional hazards Cox regression model takes into account the time to the event. Data is reported as the numbers of subjects with the event and the Hazard ratio is included in the Statistical Analysis section attached to the Outcome Measure data table.

    Time frame: Up to 38.2 months

Secondary outcomes

  1. Time to the First Occurrence of Any of the Components of the Composite: ≥50% Sustained Decline in eGFR or Reaching ESRD or Renal Death.

    End Stage Renal Disease (ESRD) is defined as: * Sustained eGFR \<15 mL/min/1.73m2 or, * Chronic dialysis treatment or, * Receiving a renal transplant The proportional hazards Cox regression model takes into account the time to the event. Data is reported as the numbers of subjects with the event and the Hazard ratio is included in the Statistical Analysis section attached to the Outcome Measure data table.

    Time frame: Up to 38.2 months

  2. Time to the First Occurrence of Either of the Components of the Composite: CV Death or Hospitalization for Heart Failure.

    The proportional hazards Cox regression model takes into account the time to the event. Data is reported as the numbers of subjects with the event and the Hazard ratio is included in the Statistical Analysis section attached to the Outcome Measure data table.

    Time frame: Up to 38.2 months

  3. Time to Death From Any Cause.

    The proportional hazards Cox regression model takes into account the time to the event. Data is reported as the numbers of subjects with the event and the Hazard ratio is included in the Statistical Analysis section attached to the Outcome Measure data table.

    Time frame: Up to 38.2 months

07

Results

Posted Jul 7, 2021

Participant flow

Participant flow — Overall Study
MilestoneDapagliflozinPlacebo
Started21522152
Completed21422147
Not completed105
Withdrew: Withdrawal by subject83
Withdrew: Lost to follow-up22

Outcome measures

PrimaryTime to the First Occurrence of Any of the Components of the Composite: ≥50% Sustained Decline in eGFR or Reaching ESRD or CV Death or Renal Death.

End Stage Renal Disease (ESRD) is defined as: * Sustained eGFR \<15 mL/min/1.73m2 or, * Chronic dialysis treatment or, * Receiving a renal transplant The proportional hazards Cox regression model takes into account the time to the event. Data is reported as the numbers of subjects with the event and the Hazard ratio is included in the Statistical Analysis section attached to the Outcome Measure data table.

Time frame:
Up to 38.2 months
Reported as:
Count of participants · Participants
Time to the First Occurrence of Any of the Components of the Composite: ≥50% Sustained Decline in eGFR or Reaching ESRD or CV Death or Renal Death.
ParticipantsDapagliflozinPlacebo
Time to the First Occurrence of Any of the Components of the Composite: ≥50% Sustained Decline in eGFR or Reaching ESRD or CV Death or Renal Death.197312
Statistical analysis
  • Dapagliflozin vs Placebo · Regression, Cox · p = < 0.0001 · Hazard ratio (hr): 0.61 · 95% CI 0.51 to 0.72Stratified by randomization stratification of Type 2 Diabetes and urine albumin creatinine ratio and adjusting for baseline eGFR.
SecondaryTime to the First Occurrence of Any of the Components of the Composite: ≥50% Sustained Decline in eGFR or Reaching ESRD or Renal Death.

End Stage Renal Disease (ESRD) is defined as: * Sustained eGFR \<15 mL/min/1.73m2 or, * Chronic dialysis treatment or, * Receiving a renal transplant The proportional hazards Cox regression model takes into account the time to the event. Data is reported as the numbers of subjects with the event and the Hazard ratio is included in the Statistical Analysis section attached to the Outcome Measure data table.

Time frame:
Up to 38.2 months
Reported as:
Count of participants · Participants
Time to the First Occurrence of Any of the Components of the Composite: ≥50% Sustained Decline in eGFR or Reaching ESRD or Renal Death.
ParticipantsDapagliflozinPlacebo
Time to the First Occurrence of Any of the Components of the Composite: ≥50% Sustained Decline in eGFR or Reaching ESRD or Renal Death.142243
Statistical analysis
  • Dapagliflozin vs Placebo · Regression, Cox · p = < 0.0001 · Hazard ratio (hr): 0.56 · 95% CI 0.45 to 0.68Stratified by randomization stratification of Type 2 Diabetes and urine albumin creatinine ratio and adjusting for baseline eGFR.
SecondaryTime to the First Occurrence of Either of the Components of the Composite: CV Death or Hospitalization for Heart Failure.

The proportional hazards Cox regression model takes into account the time to the event. Data is reported as the numbers of subjects with the event and the Hazard ratio is included in the Statistical Analysis section attached to the Outcome Measure data table.

Time frame:
Up to 38.2 months
Reported as:
Count of participants · Participants
Time to the First Occurrence of Either of the Components of the Composite: CV Death or Hospitalization for Heart Failure.
ParticipantsDapagliflozinPlacebo
Time to the First Occurrence of Either of the Components of the Composite: CV Death or Hospitalization for Heart Failure.100138
Statistical analysis
  • Dapagliflozin vs Placebo · Regression, Cox · p = 0.0089 · Hazard ratio (hr): 0.71 · 95% CI 0.55 to 0.92Stratified by randomization stratification of Type 2 Diabetes and urine albumin creatinine ratio and adjusting for baseline eGFR.
SecondaryTime to Death From Any Cause.

The proportional hazards Cox regression model takes into account the time to the event. Data is reported as the numbers of subjects with the event and the Hazard ratio is included in the Statistical Analysis section attached to the Outcome Measure data table.

Time frame:
Up to 38.2 months
Reported as:
Count of participants · Participants
Time to Death From Any Cause.
ParticipantsDapagliflozinPlacebo
Time to Death From Any Cause.101146
Statistical analysis
  • Dapagliflozin vs Placebo · Regression, Cox · p = 0.0035 · Hazard ratio (hr): 0.69 · 95% CI 0.53 to 0.88Stratified by randomization stratification of Type 2 Diabetes and urine albumin creatinine ratio and adjusting for baseline eGFR.

Adverse events

Collected over Up to 39.2 months. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dapa 10 mg107/2,152 (5%)633/2,149 (29.5%)479/2,149 (22.3%)
Placebo159/2,152 (7.4%)729/2,149 (33.9%)500/2,149 (23.3%)
Most frequent serious events
Showing 10 of 679
Most frequent serious events
EventDapa 10 mgPlacebo
PneumoniaInfections and infestations44/214970/2149
Cardiac failureCardiac disorders39/214959/2149
Acute kidney injuryRenal and urinary disorders39/214952/2149
Acute myocardial infarctionCardiac disorders32/214946/2149
End stage renal diseaseRenal and urinary disorders26/214936/2149
Chronic kidney diseaseRenal and urinary disorders20/214931/2149
Ischaemic strokeNervous system disorders22/214928/2149
DeathGeneral disorders15/214927/2149
Angina unstableCardiac disorders14/214922/2149
Cardiac failure congestiveCardiac disorders13/214922/2149
Most frequent other events
Showing 10 of 11
Most frequent other events
EventDapa 10 mgPlacebo
NasopharyngitisInfections and infestations92/214981/2149
Urinary tract infectionInfections and infestations78/214979/2149
HypoglycaemiaMetabolism and nutrition disorders74/214970/2149
Renal impairmentRenal and urinary disorders51/214964/2149
Oedema peripheralGeneral disorders54/214963/2149
HypertensionVascular disorders62/214960/2149
Glomerular filtration rate decreasedInvestigations39/214961/2149
HyperkalaemiaMetabolism and nutrition disorders53/214949/2149
Back painMusculoskeletal and connective tissue disorders44/214950/2149
Acute kidney injuryRenal and urinary disorders49/214944/2149

Baseline characteristics

Age, Continuous
Age, Continuous(Years)DapagliflozinPlaceboTotal
Mean61.8 ± 12.161.9 ± 12.161.8 ± 12.1
Age, Customized
Age, Customized(Participants)DapagliflozinPlaceboTotal
<= 50 years362370732
> 50 years179017823572
Age, Customized
Age, Customized(Participants)DapagliflozinPlaceboTotal
<= 65 years124712392486
> 65 years9059131818
Age, Customized
Age, Customized(Participants)DapagliflozinPlaceboTotal
<=65 years124712392486
66-75 years6636671330
> 75 years242246488
Sex: Female, Male
Sex: Female, Male(Participants)DapagliflozinPlaceboTotal
Female7097161425
Male144314362879
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)DapagliflozinPlaceboTotal
Hispanic or Latino5225501072
Not Hispanic or Latino163016023232
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)DapagliflozinPlaceboTotal
White112411662290
Black or African American10487191
Asian7497181467
Native Hawaiian or Other Pacific Islander112
American Indian or Alaska Native6274136
Other112106218
Most likely etiology of CKD
Most likely etiology of CKD(Participants)DapagliflozinPlaceboTotal
Diabetic Nephropathy127112392510
Ischaemic/Hypertensive Nephropathy324363687
Chronic Glomerulonephritis343352695
Other or unknown cause of CKD214198412

3 further baseline measures are reported on the registry.

08

Study locations

392 sites
  • Research Site
    Birmingham, Alabama 35233, United States
  • Research Site
    Hawaiian Gardens, California 90716, United States
  • Research Site
    Lomita, California 90717, United States
  • Research Site
    Los Angeles, California 90022, United States
  • Research Site
    Palo Alto, California 94304, United States
  • Research Site
    San Dimas, California 91773, United States
  • Research Site
    San Ramon, California 94582, United States
  • Research Site
    Vista, California 92083, United States
  • Research Site
    Aurora, Colorado 80045, United States
  • Research Site
    Denver, Colorado 80246, United States
  • Research Site
    Boynton Beach, Florida 33435, United States
  • Research Site
    Boynton Beach, Florida 33472, United States
  • Research Site
    Jacksonville, Florida 32224, United States
  • Research Site
    Miami Lakes, Florida 33014, United States
  • Research Site
    Miami, Florida 33015, United States
  • Research Site
    Miami, Florida 33144, United States
  • Research Site
    Miami, Florida 33165, United States
  • Research Site
    Naples, Florida 34102, United States
  • Research Site
    New Port Richey, Florida 34652, United States
  • Research Site
    Atlanta, Georgia 30342-1797, United States
  • Research Site
    Augusta, Georgia 30904, United States
  • Research Site
    Chicago, Illinois 60643, United States
  • Research Site
    Iowa City, Iowa 52242, United States
  • Research Site
    Topeka, Kansas 66606, United States
  • Research Site
    Wichita, Kansas 67214, United States
  • Research Site
    Metairie, Louisiana 70006, United States
  • Research Site
    Boston, Massachusetts 02111, United States
  • Research Site
    Detroit, Michigan 48202, United States
  • Research Site
    Flint, Michigan 48504, United States
  • Research Site
    Duluth, Minnesota 55805, United States
  • Research Site
    Omaha, Nebraska 68105, United States
  • Research Site
    Albany, New York 12208, United States
  • Research Site
    Asheville, North Carolina 28801, United States
  • Research Site
    Charlotte, North Carolina 28207, United States
  • Research Site
    Hickory, North Carolina 28601, United States
  • Research Site
    New Bern, North Carolina 28562, United States
  • Research Site
    Winston-Salem, North Carolina 27103, United States
  • Research Site
    Cincinnati, Ohio 45219, United States
  • Research Site
    Maumee, Ohio 43537, United States
  • Research Site
    Jersey Shore, Pennsylvania 17740, United States
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Research Site
    Greer, South Carolina 29651, United States
  • Research Site
    Kingsport, Tennessee 37660, United States
  • Research Site
    Nashville, Tennessee 37232, United States
  • Research Site
    El Paso, Texas 79935, United States
  • Research Site
    Fort Worth, Texas 76116, United States
  • Research Site
    Fort Worth, Texas 76117, United States
  • Research Site
    Fort Worth, Texas 76164, United States
  • Research Site
    Houston, Texas 77004, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Odessa, Texas 79761, United States
  • Research Site
    Burke, Virginia 22015, United States
  • Research Site
    Manassas, Virginia 20110, United States
  • Research Site
    Newport News, Virginia 23606, United States
  • Research Site
    Tacoma, Washington 98405, United States
  • Research Site
    Buenos Aires, ARG 1425, Argentina
  • Research Site
    Buenos Aires, C1425BGN, Argentina
  • Research Site
    Buenos Aires, C1429BWN, Argentina
  • Research Site
    Caba, C1119ACN, Argentina
  • Research Site
    Caba, C1120AAC, Argentina
  • Research Site
    Ciudad Autonoma Buenos Aires, 1093, Argentina
  • Research Site
    Ciudad Autonoma de Buenos Aire, C1407GTN, Argentina
  • Research Site
    Cordoba, 5000, Argentina
  • Research Site
    Cordoba, X5006CBI, Argentina
  • Research Site
    Corrientes, W3400AMZ, Argentina
  • Research Site
    Córdoba, 5000, Argentina
  • Research Site
    Córdoba, X5016LIG, Argentina
  • Research Site
    Mar del Plata, 7600, Argentina
  • Research Site
    Mar del Plata, B7600FZN, Argentina
  • Research Site
    Nueve de julio, B6500EZL, Argentina
  • Research Site
    Rosario, S2000DEJ, Argentina
  • Research Site
    San Luis, D5700CTA, Argentina
  • Research Site
    San Miguel de Tucuman, 4000, Argentina
  • Research Site
    San Miguel de Tucuman, T4000ICL, Argentina
  • Research Site
    San Nicolás, B2900DMH, Argentina
  • Research Site
    Santa Fe, 3000, Argentina
  • Research Site
    Santa Rosa, 6300, Argentina
  • Research Site
    Botucatu, 18.618-686, Brazil
  • Research Site
    Campinas, 13010-001, Brazil
  • Research Site
    Caxias do Sul, 95070-560, Brazil
  • Research Site
    Curitiba, 80440-020, Brazil
  • Research Site
    Joinville, 89227-680, Brazil
  • Research Site
    Porto Alegre, 90020-090, Brazil
  • Research Site
    Porto Alegre, 90035-903, Brazil
  • Research Site
    Porto Alegre, 90610-000, Brazil
  • Research Site
    Salvador, 40415-065, Brazil
  • Research Site
    Santo Andre, 09090-790, Brazil
  • Research Site
    Sao Paulo, 04039-000, Brazil
  • Research Site
    Sao Paulo, 05403-000, Brazil
  • Research Site
    São José do Rio Preto, 15090-000, Brazil
  • Research Site
    São Paulo, 01228-000, Brazil
  • Research Site
    Edmonton, Alberta T6H 2L4, Canada
  • Research Site
    Red Deer, Alberta T4N 6V7, Canada
  • Research Site
    Vancouver, British Columbia V6Z 1Y6, Canada
  • Research Site
    Halifax, Nova Scotia B3H 1V7, Canada
  • Research Site
    Brampton, Ontario L6S 0C6, Canada
  • Research Site
    Concord, Ontario L4K 4M2, Canada
  • Research Site
    Etobicoke, Ontario M9R 4E1, Canada
  • Research Site
    Kingston, Ontario K7L 2V7, Canada
  • Research Site
    London, Ontario N6A 5A5, Canada

Showing the first 100 of 392 sites across 21 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • McEwan P, Darlington O, Miller R, McMurray JJV, Wheeler DC, Heerspink HJL, Briggs A, Bergenheim K, Garcia Sanchez JJ. Cost-Effectiveness of Dapagliflozin as a Treatment for Chronic Kidney Disease: A Health-Economic Analysis of DAPA-CKD. Clin J Am Soc Nephrol. 2022 Dec;17(12):1730-1741. doi: 10.2215/CJN.03790322. Epub 2022 Nov 2. PubMed 36323444 ↗
  • Jongs N, Chertow GM, Greene T, McMurray JJV, Langkilde AM, Correa-Rotter R, Kashihara N, Rossing P, Sjostrom CD, Stefansson BV, Toto RD, Wheeler DC, Heerspink HJL; DAPA-CKD Trial Committees and Investigators; Members of the DAPA-CKD Trial Committees and Investigators. Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD. J Am Soc Nephrol. 2022 Nov;33(11):2094-2107. doi: 10.1681/ASN.2022030306. Epub 2022 Aug 17. PubMed 35977807 ↗
  • Vart P, Correa-Rotter R, Hou FF, Jongs N, Chertow GM, Langkilde AM, McMurray JJV, Rossing P, Sjostrom CD, Stefansson BV, Toto RD, Douthat W, Escudero E, Isidto R, Khullar D, Bajaj HS, Wheeler DC, Heerspink HJL. Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions. Kidney Int Rep. 2022 Feb 2;7(4):699-707. doi: 10.1016/j.ekir.2022.01.1060. eCollection 2022 Apr. PubMed 35497805 ↗
  • Waijer SW, Vart P, Cherney DZI, Chertow GM, Jongs N, Langkilde AM, Mann JFE, Mosenzon O, McMurray JJV, Rossing P, Correa-Rotter R, Stefansson BV, Toto RD, Wheeler DC, Heerspink HJL. Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial. Diabetologia. 2022 Jul;65(7):1085-1097. doi: 10.1007/s00125-022-05694-6. Epub 2022 Apr 21. PubMed 35445820 ↗
  • Heerspink HJL, Jongs N, Chertow GM, Langkilde AM, McMurray JJV, Correa-Rotter R, Rossing P, Sjostrom CD, Stefansson BV, Toto RD, Wheeler DC, Greene T; DAPA-CKD Trial Committees and Investigators. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021 Nov;9(11):743-754. doi: 10.1016/S2213-8587(21)00242-4. Epub 2021 Oct 4. Erratum In: Lancet Diabetes Endocrinol. 2022 Oct;10(10):e10. doi: 10.1016/S2213-8587(22)00223-6. PubMed 34619108 ↗
  • Jongs N, Greene T, Chertow GM, McMurray JJV, Langkilde AM, Correa-Rotter R, Rossing P, Sjostrom CD, Stefansson BV, Toto RD, Wheeler DC, Heerspink HJL; DAPA-CKD Trial Committees and Investigators. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021 Nov;9(11):755-766. doi: 10.1016/S2213-8587(21)00243-6. Epub 2021 Oct 4. PubMed 34619106 ↗
  • McMurray JJV, Wheeler DC, Stefansson BV, Jongs N, Postmus D, Correa-Rotter R, Chertow GM, Hou FF, Rossing P, Sjostrom CD, Solomon SD, Toto RD, Langkilde AM, Heerspink HJL; DAPA-CKD Trial Committees and Investigators. Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure. JACC Heart Fail. 2021 Nov;9(11):807-820. doi: 10.1016/j.jchf.2021.06.017. Epub 2021 Aug 23. Erratum In: JACC Heart Fail. 2022 Jun;10(6):446-447. doi: 10.1016/j.jchf.2022.04.001. PubMed 34446370 ↗
  • Persson F, Rossing P, Vart P, Chertow GM, Hou FF, Jongs N, McMurray JJV, Correa-Rotter R, Bajaj HS, Stefansson BV, Toto RD, Langkilde AM, Wheeler DC, Heerspink HJL; DAPA-CKD Trial Committees and Investigators. Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial. Diabetes Care. 2021 Aug;44(8):1894-1897. doi: 10.2337/dc21-0300. Epub 2021 Jun 28. PubMed 34183431 ↗
  • Wheeler DC, Stefansson BV, Jongs N, Chertow GM, Greene T, Hou FF, McMurray JJV, Correa-Rotter R, Rossing P, Toto RD, Sjostrom CD, Langkilde AM, Heerspink HJL; DAPA-CKD Trial Committees and Investigators. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021 Jan;9(1):22-31. doi: 10.1016/S2213-8587(20)30369-7. PubMed 33338413 ↗
  • McMurray JJV, Wheeler DC, Stefansson BV, Jongs N, Postmus D, Correa-Rotter R, Chertow GM, Greene T, Held C, Hou FF, Mann JFE, Rossing P, Sjostrom CD, Toto RD, Langkilde AM, Heerspink HJL; DAPA-CKD Trial Committees and Investigators. Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease. Circulation. 2021 Feb 2;143(5):438-448. doi: 10.1161/CIRCULATIONAHA.120.051675. Epub 2020 Nov 13. PubMed 33186054 ↗
  • Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjostrom CD, Toto RD, Langkilde AM, Wheeler DC; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24. PubMed 32970396 ↗
  • Wheeler DC, Stefansson BV, Batiushin M, Bilchenko O, Cherney DZI, Chertow GM, Douthat W, Dwyer JP, Escudero E, Pecoits-Filho R, Furuland H, Gorriz JL, Greene T, Haller H, Hou FF, Kang SW, Isidto R, Khullar D, Mark PB, McMurray JJV, Kashihara N, Nowicki M, Persson F, Correa-Rotter R, Rossing P, Toto RD, Umanath K, Van Bui P, Wittmann I, Lindberg M, Sjostrom CD, Langkilde AM, Heerspink HJL. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrol Dial Transplant. 2020 Oct 1;35(10):1700-1711. doi: 10.1093/ndt/gfaa234. PubMed 32862232 ↗
  • Piperidou A, Loutradis C, Sarafidis P. SGLT-2 inhibitors and nephroprotection: current evidence and future perspectives. J Hum Hypertens. 2021 Jan;35(1):12-25. doi: 10.1038/s41371-020-00393-4. Epub 2020 Aug 10. PubMed 32778748 ↗
  • Sternlicht HK, Bakris GL. Reductions in albuminuria with SGLT2 inhibitors: a marker for improved renal outcomes in patients without diabetes? Lancet Diabetes Endocrinol. 2020 Jul;8(7):553-555. doi: 10.1016/S2213-8587(20)30185-6. No abstract available. PubMed 32559465 ↗
  • Gonzalez DE, Foresto RD, Ribeiro AB. SGLT-2 inhibitors in diabetes: a focus on renoprotection. Rev Assoc Med Bras (1992). 2020 Jan 13;66Suppl 1(Suppl 1):s17-s24. doi: 10.1590/1806-9282.66.S1.17. PubMed 31939531 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Jun 2020, 40 months.

Results were first posted in Jul 2021, 1 year after primary completion.

Of 104 industry-sponsored phase 3 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 49. This study's 40 months is above that.

Counting every sponsor, half of 145 studies reached it within 32 months; a quarter within 19 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2017
First posted
Jan 30, 2017
StartActual
Feb 2, 2017
Primary completionActual
Jun 12, 2020
CompletionActual
Jun 12, 2020
Results first posted
Jul 7, 2021
Last update
Jul 7, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03036150
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jan 30, 2017
Start date
Feb 2, 2017
Primary completion
Jun 12, 2020
Completion
Jun 12, 2020
Results posted
Jul 7, 2021
Last update
Jul 7, 2021

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapagliflozin

Start the discussion